5-Fluorouracil for genital warts
A Cochrane review 1 included 6 studies with a total of 988 subjects (645 women and 343 men). 5-Fluorouracil (5–FU) presented better results for cure than placebo or no treatment (RR 0.39, 95% CI 0.23 to 0.67; 3 trials, n=209), meta-cresol-sulfonic acid (MCSA) (RR 2.11, 95% CI 0.83 to 5.37; 1 trial, n=83), and podophyllin 2%, 4% or 25% (RR 1.26, 95% CI 0.86 to 1.82, 2 trials, n=156). There were no statistical differences for treatment failure for 5-FU vs CO2 Laser (RR 0.69, 95% CI 0.43 to 1.11; 1 trial, n=49),or 5-FU vs 5-FU + INFα-2a (low dose) (RR 1.02, 95% CI 0.87 to 1.119). The concentration of 5-FU varied in different studies.
Comment: The quality of evidence is downgraded by several shortcomings in study quality, by inconsistency (heterogeneity in interventions and outcomes), and by imprecise results (limited study size for each comparison).
1. Batista CS, Atallah AN, Saconato H, da Silva EM. 5-FU for genital warts in non-immunocompromised individuals. Cochrane Database Syst Rev 2010 Apr 14;4:CD006562. [PMID:20393949]
Copyright © 2020 Duodecim Medical Publications Limited.
Evidence Central is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research. Complete Product Information.